Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.95 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.95 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.95 |
| ▸ | THPO | P40225 | 1/20 | 0.95 |
| ▸ | CYP2E1 | P05181 | 4/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.59 |
| ▸ | CYP2B6 | P20813 | 4/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.59 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.59 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2386 | 0.97 | CYP2C19 (1.00) | BLMPMP22CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL6449000 | 0.84 | CYP2C19 (0.75) | BLMPMP22CYP2C19CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL9018599 | 0.81 | BLM (0.68) | BLMPMP22CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL31244037 | 0.80 | CYP2C19 (0.70) | BLMPMP22CYP2C19CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL25239520 | 0.78 | BLM (0.64) | BLMPMP22CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL1444744 | 0.78 | CYP1A2 (0.67) | BLMPMP22CYP2C19CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL21803751 | 0.76 | BLM (0.61) | BLMPMP22CYP2C19CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL21803742 | 0.76 | BLM (0.61) | BLMPMP22CYP2C19CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL25234072 | 0.76 | BLM (0.61) | BLMPMP22CYP2C19CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL25281417 | 0.76 | BLM (0.61) | BLMPMP22CYP2C19CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380319-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2022-12-01 | — | — | US | disclosed |
| EP-4031532-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Bial-R&D Investments, S.A. (PT) | 2022-07-27 | — | — | EP | disclosed |
| CN-114787136-A | Substituted benzimidazole carboxamides and their use in the treatment of medical disorders | 比亚尔R&D投资股份公司 | 2022-07-22 | — | — | CN | disclosed |
| US-20210403470-A1 | NOVEL METHODS FOR PREPARATION OF SUBSTITUTED PYRIDINES AND RELATED NOVEL COMPOUNDS | WATKINS EDMOND BLAKE (US) | 2021-12-30 | — | — | US | disclosed |
| US-11117893-B2 | Methods for preparation of substituted pyridines and related novel compounds | UNION UNIVERSITY (US) | 2021-09-14 | — | — | US | disclosed |
| WO-2021055591-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL-BioTech Investments, Inc. (US) | 2021-03-25 | — | — | WO | disclosed |
| US-20200095245-A1 | NOVEL METHODS FOR PREPARATION OF SUBSTITUTED PYRIDINES AND RELATED NOVEL COMPOUNDS | UNION UNIVERSITY | 2020-03-26 | — | — | US | disclosed |
| US-20170029367-A1 | Substituted Aromatic Sulfur Compounds and Methods of Their Use | CEPHALON INC (US) | 2017-02-02 | — | — | US | disclosed |
| US-9475766-B2 | Substituted aromatic sulfur compounds and methods of their use | CEPHALON, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-20140005175-A1 | Substituted Aromatic Sulfur Compounds and Methods of Their Use | CEPHALON, INC. (US) | 2014-01-02 | — | — | US | disclosed |
| US-8058243-B2 | Method for treating a brain cancer with ifenprodil | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2011-11-15 | — | — | US | disclosed |
| US-20090076019-A1 | METHODS FOR TREATING NEUROLOGICAL DISORDERS OR DAMAGE | MOUNT SINAI HOSPITAL (CA) | 2009-03-19 | — | — | US | disclosed |
| US-6395730-B1 | CARDIOVASCULAR DISORDERS | ICAGEN, INC. | 2002-05-28 | — | — | US | disclosed |
| EP-1082315-A1 | POTASSIUM CHANNEL INHIBITORS | Icagen, Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| US-6174908-B1 | TREATING DISEASE, CONDITION, OR DISORDER WHICH RESPONDS TO INHIBITION OF POTASSIUM CHANNEL FUNCTION BY ADMINISTERING THIAZOLIDONE OR METATHIAZONONE COMPOUND, ITS SALT, AMIDE, ESTER, COMPLEX, CHELATE, HYDRATE, STEREOISOMER, METABOLITE | ICAGEN, INC. | 2001-01-16 | — | — | US | disclosed |
| WO-1999062891-A1 | POTASSIUM CHANNEL INHIBITORS | ICAGEN, INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| EP-0658803-B1 | A class of compounds which increases and stabilizes photographic speed | EASTMAN KODAK CO (US) | 1998-09-02 | — | — | EP | disclosed |
| US-5707931-A | 4-amino-2-quinolinone derivatives | KOREA RESEARCH INTSITUTED OF CHEMICAL TECHNOLOGY (KR) | 1998-01-13 | — | — | US | disclosed |
| US-5500333-A | OXAZOLE OR THIAZOLE COMPOUNDS CONTAINING ALKYNE GROUP | EASTMAN KODAK COMPANY (US) | 1996-03-19 | — | — | US | disclosed |
| EP-0658803-A1 | A class of compounds which increases and stabilizes photographic speed | EASTMAN KODAK COMPANY (US) | 1995-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403470-A1 | NOVEL METHODS FOR PREPARATION OF SUBSTITUTED PYRIDINES AND RELATED NOVEL COMPOUNDS | WEE1, WEE2, THEM6 | HTR2A 3441/4885BLM 4128/4885PMP22 788/4885 |
| US-11117893-B2 | Methods for preparation of substituted pyridines and related novel compounds | NNMT, CYP4F3, AGPS | HTR2A 3526/4885BLM 3982/4885PMP22 772/4885 |
| US-20140005175-A1 | Substituted Aromatic Sulfur Compounds and Methods of Their Use | RB1, NRAS, TP53 | HTR2A 2606/4885BLM 761/4885PMP22 2508/4885 |
| US-20170029367-A1 | Substituted Aromatic Sulfur Compounds and Methods of Their Use | RB1, NRAS, TP53 | HTR2A 2606/4885BLM 761/4885PMP22 2508/4885 |
| US-20200095245-A1 | NOVEL METHODS FOR PREPARATION OF SUBSTITUTED PYRIDINES AND RELATED NOVEL COMPOUNDS | WEE1, WEE2, THEM6 | HTR2A 3441/4885BLM 4128/4885PMP22 788/4885 |
| US-20220380319-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GAA, GBA1, CLN6 | HTR2A 2441/4885BLM 2622/4885PMP22 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.